使用过氧化氢/全氟戊烷相变纳米颗粒与低强度聚焦超声实现稳定的低剂量氧释放用于冠状动脉溶栓
研究在体外人工循环系统中比较磷酸盐缓冲液、SonoVue微泡与过氧化氢/全氟戊烷相变纳米颗粒联合低强度聚焦超声的溶栓和氧释放效率。含3%过氧化氢的纳米颗粒粒径456.7±31.2 nm、电荷-37.5±5.22 mV,溶栓失重322.0±40.8 mg、溶栓率54.8±5.7%,显著高于空白对照组和SonoVue组(p<0.01),并实现稳定的低流量氧供。
要点
- 含3%过氧化氢的过氧化氢/全氟戊烷相变纳米颗粒粒径456.7±31.2 nm、电荷-37.5±5.22 mV,载药与低剂量氧释放稳定。
- 联合低强度聚焦超声时,该纳米颗粒溶栓失重322.0±40.8 mg、溶栓率54.8±5.7%,高于SonoVue微泡和磷酸盐缓冲液对照组(p<0.01)。
- 该体外人工循环系统结果提示该方案溶栓效率高且可稳定供氧,为急性心肌梗死新疗法提供实验基础。
核心结论
- 过氧化氢/全氟戊烷相变纳米颗粒联合低强度聚焦超声在体外人工循环系统中表现出高溶栓效率和稳定的低流量氧供,为急性心肌梗死新治疗方法的建立提供实验基础。
研究设计与样本
- 体外实验研究,设三组:A组为磷酸盐缓冲液空白对照,B组为SonoVue微泡,C组为过氧化氢/全氟戊烷相变纳米颗粒;纳米颗粒采用双乳化法制备,实验在连接低强度聚焦超声系统和溶解氧检测器的人工循环系统中进行。
诊断标准与关键数值
- C组选用含3%过氧化氢的过氧化氢/全氟戊烷相变纳米颗粒(平均粒径456.7±31.2 nm,电荷-37.5±5.22 mV),因体外实验中载药能力和稳定低剂量氧释放效率最佳。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
After the onset of myocardial infarction, extensive coronary thrombus and oxygen supply insufficiency lead to severe myocardial damage and heart failure. Recently, ultrasound-irradiated phase-change nanoparticles have been recognized for their cardiovascular thrombolysis potential. Therefore, we sought to establish a novel treatment method using hydrogen peroxide (H2O2)/perfluoropentane (PFP) phase-change nanoparticles with low-intensity focused ultrasound (LIFU) for the simulation of acute coronary thrombolysis and myocardial preservation. There were three groups in our study: Group A consisted of phosphate-buffered saline (PBS) as the blank control, group B consisted of SonoVue microbubbles and group C consisted of H2O2/PFP phase-change nanoparticles. The H2O2/PFP phase-change nanoparticles were prepared using a double-emulsification process. The in vitro experiments were conducted in an artificial circulatory system connected to an LIFU system and dissolved oxygen detector. Thrombolysis efficiency and oxygen release efficiency were compared among the groups. H2O2/PFP nanoparticles with 3% H2O2 (average size: 456.7 ± 31.2 nm, charge: -37.5 ± 5.22 mV) was the optimal selection in group C because of the stable loading capacity and stable low-dose oxygen release efficiency in the in vitro experiments. Thrombolytic weight loss and loss rates in group C (322.0 ± 40.8 mg, 54.8 ± 5.7%) were significantly higher than those in group A (36.2 ± 18.1 mg, 5.5 ± 2.5%) and group B (91.0 ± 11.9 mg, 14.3 ± 2.4%) (p < 0.01). The innovative method using H2O2/PFP phase-change nanoparticles with LIFU exhibited high thrombolytic efficiency and stable low-flow oxygen supply in the artificial circulatory system, providing a solid experimental foundation for the establishment of a novel treatment method for acute myocardial infarction.
引用
- Jiang N, Hu B, Cao S, et al. Stable Low-Dose Oxygen Release Using H2O2/Perfluoropentane Phase-Change Nanoparticles with Low-Intensity Focused Ultrasound for Coronary Thrombolysis. Ultrasound Med Biol. 2020. PMID: 32646686. doi:10.1016/j.ultrasmedbio.2020.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。